Skip to content

Clinical trials

Muscular Dystrophy, Facioscapulohumeral trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Muscular Dystrophy, Facioscapulohumeral Country / region: United States Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20051
20122
20131
20142
20153
20164
20171
20181
20192
20201
20211
20221
20232
20242
20255
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Recruiting9
Terminated5
Active, not recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
aTyr Pharma, Inc.5
Avidity Biosciences, Inc.3
Fulcrum Therapeutics3
University of Kansas Medical Center3
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA2
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.2
University of Rochester2
Cooperative International Neuromuscular Research Group1
Epicrispr Biotechnologies, Inc.1
FSHD Society1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Muscular Dystrophy, Facioscapulohumeral32
Muscular Dystrophies9
Neuromuscular Diseases4
Muscular Dystrophies, Limb-Girdle3
Muscular Dystrophy, Duchenne3
Musculoskeletal Diseases3
Myotonic Dystrophy3
Charcot-Marie-Tooth Disease2
Muscular Atrophy, Spinal2
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2

Trials

Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.